Fluocinolone Acetonide Implant Injected 1 Month after Dexamethasone Implant for Diabetic Macular Oedema: the ILUVI1MOIS Study

• DOI: 10.1007/s40123-023-00749-2
• Publication Date: 2023-06-27T17:01:42Z
• Authors: Nicolas Rousseau; Olivier Lebreton; Hélène Masse; Yann Maucourant; Valentin Pipelart; Manon Clement; Marie-Laure Le Lez; Raoul Kanav Khanna; Maxime Pepin; Yannick Eude; Guylène Le Meur; Michel Weber; Jean-Baptiste Duc...
• Keywords: Fluocinolone acetonide; Corticosteroid implant; [SDV]Life Sciences [q-bio]; Brief Report; intravitreal injection; dexamethasone; Diabetic macular oedema; RE1-994; Dexamethasone; 3. Good health; Ophthalmology; retinal diseases; Diabetes complications; diabetic macular oedema; DME; fluocinolone acetonide; corticosteroid implant

The aim of this study was to assess the efficacy and safety of fluocinolone acetonide implant (FAci) injected 1 month after the last dexamethasone intravitreal implant (DEXi) in chronic diabetic macular oedema (DME) patients.Retrospective multicentric study conducted in pseudophakic patients with chronic DME frequently treated with dexamethasone intravitreal implant (DEXi; time to DME recurrence ≤ 6 months), receiving FAci 1 month after the last DEXi, with at least a 6-month follow-up. Best-corrected visual acuity (BCVA), central macular thickness (CMT) on optical coherence tomography, intraocular pressure (IOP) and additional treatments were assessed on the day of FAci injection (M0), 1 (M1) and 3 months (M3) later and then every 3 months.A total of 41 eyes from 34 patients were included. At M0, patients' mean age was 68.7 ± 9.8 years, the mean DME duration was 63.9 ± 22.9 months, the mean interval between two DEXi was 14.2 ± 3.3 weeks. M12 data were available for 71% of patients. At baseline, the mean BCVA, CMT and IOP were 63.2 ± 16.6 letters, 299.4 ± 103.3 µm, and 16.2 ± 4.5 mmHg, respectively, and remained stable during the follow-up. At M12, 14% of patients required additional intravitreal treatments.In pseudophakic patients with chronic DME showing good response to DEXi but requiring repeated injections every < 6 months, switching to FAci 1 month after the last DEXi was effective and safe. Further prospective randomized controlled studies are needed to confirm these findings, and to determine the best interval between the last DEXi and the first FAci.